Pharmacokinetics and Pharmacodynamics of Therapeutic-Dose Rivaroxaban Prior to and Early After Bariatric Surgery

Background/Objectives: Direct oral anticoagulants (DOAC) are widely used for the prevention and treatment of venous thromboembolism (VTE) in the general population. However, evidence on their efficacy and safety in patients undergoing bariatric surgery remains limited. The objective of this study was to investigate the effect of bariatric surgery on the pharmacokinetic (PK) and pharmacodynamic (PD) parameters of therapeutic-dose rivaroxaban. Methods: This single-centre clinical study retrospectively analysed PK/PD data from patients with a body mass index (BMI) ≥ 35 kg/m2 receiving extended anticoagulation with 20 mg rivaroxaban. Rivaroxaban PK (plasma concentrations) and PD (prothrombin fragments F1 + 2 and D-dimers) parameters were repeatedly measured prior to and up to 3 months after bariatric surgery. Results: Nine patients (mean age 50 years, 78% female) with a mean BMI of 46.8 kg/m2 were included; seven patients underwent sleeve gastrectomy and two underwent Roux-en-Y gastric bypass surgery. The geometric mean rivaroxaban areas under the curve (AUC) before, and at 3 days, 30 days, and 3 months after bariatric surgery were 2441.8 µg·h/L (geometric coefficient of variation (GCV) 1.44, n = 7), 2474.7 µg·h/L (GCV 1.41, n = 9), 2468.2 µg·h/L (GCV 1.74, n = 8), and 3266.4 µg·h/L (GCV 1.25, n = 6), respectively. Prothrombin fragments F1+2 showed a time-dependent decrease after rivaroxaban administration during the early postoperative period, comparable to that observed in the presurgical measurements. Mean D-dimer levels were increased immediately after bariatric surgery (consistent with a surgery-related increase), but were comparable to the presurgical measurement at later time points. Conclusions: Based on the limited PK/PD data, rivaroxaban exposure, as assessed by AUC, remained comparable to presurgical values during the first three months after bariatric surgery. These findings are exploratory and require confirmation in larger prospective studies.

Authors

Institutions

Publication Details

Journal
Journal of Clinical Medicine
Published
2026-11-17
DOI
https://doi.org/10.3390/jcm15229014
Primary Topic
Venous Thromboembolism Diagnosis and Management
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Pharmacokinetics and Pharmacodynamics of Therapeutic-Dose Rivaroxaban Prior to and Early After Bariatric Surgery

Guido Stirnimann, Sabine Schädelin, Lorenzo Alberio, Debora Bertaggia Calderara et al.
Journal of Clinical Medicine
Venous Thromboembolism Diagnosis and Management
article

Pharmacokinetics and Pharmacodynamics of Therapeutic-Dose Rivaroxaban Prior to and Early After Bariatric Surgery

Guido Stirnimann, Sabine Schädelin, Lorenzo Alberio, Debora Bertaggia Calderara, Philipp Christoph Nett, Dino Kröll, Yves Borbély, Jonas Fischer, Yannic Clerc
article en

Abstract

Background/Objectives: Direct oral anticoagulants (DOAC) are widely used for the prevention and treatment of venous thromboembolism (VTE) in the general population. However, evidence on their efficacy and safety in patients undergoing bariatric surgery remains limited. The objective of this study was to investigate the effect of bariatric surgery on the pharmacokinetic (PK) and pharmacodynamic (PD) parameters of therapeutic-dose rivaroxaban. Methods: This single-centre clinical study retrospectively analysed PK/PD data from patients with a body mass index (BMI) ≥ 35 kg/m2 receiving extended anticoagulation with 20 mg rivaroxaban. Rivaroxaban PK (plasma concentrations) and PD (prothrombin fragments F1 + 2 and D-dimers) parameters were repeatedly measured prior to and up to 3 months after bariatric surgery. Results: Nine patients (mean age 50 years, 78% female) with a mean BMI of 46.8 kg/m2 were included; seven patients underwent sleeve gastrectomy and two underwent Roux-en-Y gastric bypass surgery. The geometric mean rivaroxaban areas under the curve (AUC) before, and at 3 days, 30 days, and 3 months after bariatric surgery were 2441.8 µg·h/L (geometric coefficient of variation (GCV) 1.44, n = 7), 2474.7 µg·h/L (GCV 1.41, n = 9), 2468.2 µg·h/L (GCV 1.74, n = 8), and 3266.4 µg·h/L (GCV 1.25, n = 6), respectively. Prothrombin fragments F1+2 showed a time-dependent decrease after rivaroxaban administration during the early postoperative period, comparable to that observed in the presurgical measurements. Mean D-dimer levels were increased immediately after bariatric surgery (consistent with a surgery-related increase), but were comparable to the presurgical measurement at later time points. Conclusions: Based on the limited PK/PD data, rivaroxaban exposure, as assessed by AUC, remained comparable to presurgical values during the first three months after bariatric surgery. These findings are exploratory and require confirmation in larger prospective studies.

Journal of Clinical MedicineVol. 15(22)
University of Bern (CH), University Hospital of Bern (CH), University Hospital of Basel (CH), University of Lausanne (CH)
Venous Thromboembolism Diagnosis and Management
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon